Margulies E H, White A M, Sherry S
Drugs. 1980 Sep;20(3):179-97. doi: 10.2165/00003495-198020030-00002.
Sulfinpyrazone1 has long been recognised as a potent uricosuric agent, but has more recently been studied extensively as a platelet inhibitor and antithrombotic agent. It is active in man following oral administration and has been reported to be effective in reducing the incidence of transient ischaemic attacks, thromboembolism associated with vascular and cardiac prostheses, recurrent venous thrombosis, arteriovenous shunt thrombosis and sudden cardiac death following myocardial infarcton. Sulfinpyrazone has not been demonstrated to be effective in preventing or reducing the risk of stroke or death in patients with cerebrovascular disease with a recent history of cerebral or retinal ischaemioc attacks. The normal total dose of sulfinpyrazone as an antithrombotic agent is 800mg daily. The drug has been used continuously for up to 4 years with no serious adverse reactions or laboratory abnormalities. There has been no apparent diminution of effect with time. Sulfinpyrazone is not a substitute for conventional anticoagulant agents (e.g. the coumarin derivatives) in the treatment of venous thrombosis, but is an important drug for the treatment of conditions associated with arterial thrombosis and possibly for the prophylaxis of recurrent venous thrombosis.
磺吡酮长期以来一直被认为是一种有效的促尿酸尿剂，但最近作为血小板抑制剂和抗血栓形成剂得到了广泛研究。口服给药后在人体中具有活性，据报道可有效降低短暂性脑缺血发作、与血管和心脏假体相关的血栓栓塞、复发性静脉血栓形成、动静脉分流血栓形成以及心肌梗死后心源性猝死的发生率。尚未证明磺吡酮对近期有脑或视网膜缺血性发作病史的脑血管疾病患者预防或降低中风或死亡风险有效。作为抗血栓形成剂，磺吡酮的正常总剂量为每日800毫克。该药物已连续使用长达4年，未出现严重不良反应或实验室异常。随着时间的推移，效果没有明显减弱。在治疗静脉血栓形成方面，磺吡酮不是传统抗凝剂（如香豆素衍生物）的替代品，但它是治疗与动脉血栓形成相关病症以及可能预防复发性静脉血栓形成的重要药物。
